Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Compound psoralen (also known as Compound Psoralen granules or Fufang Buguzhi Keli) is a traditional Chinese medicine (TCM) preparation developed and manufactured by Chongqing Kerui Pharmaceutical. It is formulated as oral granules containing a mixture of herbal extracts, including *Psoralea corylifolia* (Buguzhi), *Cynomorium songaricum* (Suoyang), *Dipsacus asper* (Xuduan), *Cibotium barometz* (Gouji), *Paeonia lactiflora* (Chishao), and *Polygonatum sibiricum* (Huangjing). Compound psoralen is approved in China for the treatment of conditions associated with Kidney Yang deficiency, including lumbar muscle strain, degenerative lumbar spine disease, and lumbar and knee pain. It works by warming and tonifying the liver and kidney, strengthening bones and muscles, promoting blood circulation, and relieving pain.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on compound psoralen.